Merck's Keytruda takes home adjuvant win in melanoma, escalating early-line fight with...

cafead

Administrator
Staff member
  • cafead   Aug 05, 2021 at 11:32: AM
via Keytruda beat out placebo in staving off the recurrence of cancer as an adjuvant therapy in patients with high-risk stage II melanoma after surgery to remove their tumors, according to topline data from the KEYNOTE-716 study released Thursday.

article source
 

<